KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Association between rapid and sustained remission and clinician- and patient-reported outcomes in patients with rheumatoid arthritis: post hoc analysis of data from the SELECT-COMPARE study.

Laure Gossec, Jayesh Patel, Aditi Kadakia, Siran Fang, Yi Peng, Sander Strengholt, Peter C Taylor, Andrew Östör

Arthritis Res Ther 27(1) 123

PMID40514717
PMCIDPMC12164154
DOI10.1186/s13075-025-03580-1
发表日期2025-06-13
入排依据:未发现恶性肿瘤人群证据。
已检查 3 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 forest plot;Fig. 2:AI 判定为 forest plot;Fig. 3:AI 判定为 forest plot。
摘要

摘要

BACKGROUND: Rapid remission has been shown to be beneficial in patients with early rheumatoid arthritis (RA). This study assessed the association of rapid and sustained remission with long-term clinician- and patient-reported outcomes (CRO/PROs) in patients treated with b/tsDMARDs. METHODS: This post hoc analysis used pooled data on patients with moderately-to-severely active RA receiving upadacitinib or adalimumab from the SELECT-COMPARE trial (NCT02629159) and its open-label long-term extension (up to 5 years). This study assessed the effect of achieving rapid remission, time to remission, and time in sustained remission on CRO/PROs. Rapid remission was defined as a Disease Activity Score 28 with C-reactive protein (DAS28-CRP) < 2.6 after 12 weeks' treatment. The outcomes of interest included a variety of PROs, such as pain, fatigue, quality of life, and CROs (28 swollen/tender joint counts). Where available, outcomes were assessed for up to 5 years; mean change in outcomes, as well as adjusted odds ratios (aOR) of achieving minimal clinically important differences (MCIDs) or normative values. Multivariate regression analyses were conducted adjusting for baseline covariates. RESULTS: In total, 28% of patients (n/N = 247/865; mean disease duration: 8.2 ± 7.8 years) achieved rapid remission. Rapid remission was associated with significantly greater improvements from baseline in all outcomes at Week 26 and significantly greater odds of achieving MCIDs (aOR range: 2.2-5.6) or normative values (aOR range: 1.6-9.8) in most PROs, including pain, fatigue, and physical functioning, over the variable 5-year follow-up; significantly lower swollen/tender joint counts were also observed. Time to achieve remission was associated with better outcomes: for every month delay in achieving remission, likelihood of achieving MCIDs or normative values decreased, on average, by 13%. Increasing time spent in sustained remission was associated with long-term improvement in CRO/PROs. CONCLUSIONS: Remission is a key outcome in RA; this study showed that achieving rapid remission, as well as reducing time to achieving remission, was associated with less pain and fatigue, and better physical functioning and quality of life over 5 years. Similarly, increasing time spent in sustained remission correlated with sustained improvement in CRO/PROs. Striving for rapid, sustained remission leads to long-term benefits.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Association of rapid remission with odds of achieving MCID or normative values during 5-year follow-up. * p ≤ 0.05; ** p ≤ 0.01; *** p < 0.001. Models were adjusted for the following variables: age, sex, RA diagnosis duration group, baseline MTX dose group, baseline oral glucocorticoid dose group, baseline DAS28-CRP status, and baseline value of each outcome being evaluated. aOR, adjusted odds ratio; CI, confidence interval; DAS28-CRP, Disease Activity Score 28 with C-reactive protein; FACIT-Fatigue, Functional Assessment of Chronic Illnesses Therapy-Fatigue; HAQ-DI, Health Assessment Questionnaire – Disability Index; MCID, minimal clinically important difference; MCS, Mental Component Summary; MTX, methotrexate; PCS, Physical Component Summary; PGA, Patient’s Global Assessment; RA, rheumatoid arthritis; SF-36, 36-item Short Form survey; SJC28, swollen joint count in 28 joints; TJC28, tender joint count in 28 joints; VAS, visual analog scale
非 KM Figure
Fig. 2Fig. 2 Odds of achieving MCID or normative values for every month delay in achieving remission. * p ≤ 0.05; ** p ≤ 0.01; *** p < 0.001. Models were adjusted for the following variables: age, sex, RA diagnosis duration group, baseline MTX dose group, baseline oral glucocorticoid dose group, baseline DAS28-CRP status, and baseline value of each outcome being evaluated. aOR, adjusted odds ratio; CI, confidence interval; DAS28-CRP, Disease Activity Score 28 with C-reactive protein; FACIT-Fatigue, Functional Assessment of Chronic Illnesses Therapy-Fatigue; HAQ-DI, Health Assessment Questionnaire – Disability Index; MCID, minimal clinically important difference; MCS, Mental Component Summary; MTX, methotrexate; PCS, Physical Component Summary; PGA, Patient’s Global Assessment; RA, rheumatoid arthritis; SF-36, 36-item Short Form survey; SJC28, swollen joint count in 28 joints; TJC28, tender joint count in 28 joints; VAS, visual analog scale
非 KM Figure
Fig. 3Fig. 3 Odds of achieving MCID or normative values for every month in sustained remission at 48 weeks. * p ≤ 0.05; ** p ≤ 0.01; *** p < 0.001. Models were adjusted for the following variables: age, sex, RA diagnosis duration group, baseline MTX dose group, baseline oral glucocorticoid dose group, baseline DAS28-CRP status, and baseline value of each outcome being evaluated. aOR, adjusted odds ratio; CI, confidence interval; DAS28-CRP, Disease Activity Score 28 with C-reactive protein; FACIT-Fatigue, Functional Assessment of Chronic Illnesses Therapy-Fatigue; HAQ-DI, Health Assessment Questionnaire – Disability Index; MCID, minimal clinically important difference; MCS, Mental Component Summary; MTX, methotrexate; PCS, Physical Component Summary; PGA, Patient’s Global Assessment; RA, rheumatoid arthritis; SF-36, 36-item Short Form survey; SJC28, swollen joint count in 28 joints; TJC28, tender joint count in 28 joints; VAS, visual analog scale
非 KM Figure